{"type":"trials","record":{"id":41462,"source_id":"clinicaltrials-gov","external_id":"NCT07700147","title":"Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration","brief_summary":"The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration. The main questions this study aims to answer are: * Does the investigational device improve visual function, as assessed by best corrected visual acuity and contrast sensitivity? * What treatment-emergent adverse events occur during the study? Participants will: * Be randomized to receive either active stimulation or sham stimulation * Apply the assigned investigational device at home once daily for 30 minutes over a 12-week treatment period * Visit the study site for eye examinations and safety assessments * Return for a follow-up visit 4 weeks after the end of treatment","overall_status":"Not Yet Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Nu Eyne Co., Ltd.","enrollment":40,"countries":["South Korea"],"start_date":"2026-07-09","completion_date":"2028-04-17","last_update_date":"2026-07-13","source_url":"https://clinicaltrials.gov/study/NCT07700147","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Nu Eyne Co., Ltd.","interventions":["Transcutaneous Electrical Stimulation","Sham Transcutaneous Electrical Stimulation"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Best Corrected Visual Acuity (BCVA) Measured by ETDRS Letter Score — Baseline, Week 2, Week 6, Week 12, Week…","Change in Contrast Sensitivity — Baseline, Week 2, Week 6, Week 12, Week 16","Change From Baseline in Geographic Atrophy Maximum Diameter and Area on Fundus Autofluorescence — Baseline, Week 2, Wee…","Change From Baseline in Drusen Area and Volume on Optical Coherence Tomography (OCT) — Baseline, Week 6, Week 12, Week…","Change From Baseline in National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Score — Baseline, Week 12","Incidence of Treatment-Emergent Adverse Events (TEAEs) — Baseline through Week 16"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Dry Age-Related Macular Degeneration","AMD","Transcutaneous Electrical Stimulation","Sham Transcutaneous Electrical Stimulation"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07700147","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-07-09 to 2028-04-17","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.817Z","intervention":["Transcutaneous Electrical Stimulation","Sham Transcutaneous Electrical Stimulation"],"participants":40,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Best Corrected Visual Acuity (BCVA) Measured by ETDRS Letter Score — Baseline, Week 2, Week 6, Week 12, Week…","Change in Contrast Sensitivity — Baseline, Week 2, Week 6, Week 12, Week 16","Change From Baseline in Geographic Atrophy Maximum Diameter and Area on Fundus Autofluorescence — Baseline, Week 2, Wee…","Change From Baseline in Drusen Area and Volume on Optical Coherence Tomography (OCT) — Baseline, Week 6, Week 12, Week…","Change From Baseline in National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Score — Baseline, Week 12","Incidence of Treatment-Emergent Adverse Events (TEAEs) — Baseline through Week 16"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41462","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}